NVIDIA and Lilly are partnering to create an AI co-innovation lab in the San Francisco Bay Area, with a joint investment of up to $1 billion over five years. The lab aims to revolutionize drug discovery by combining expertise in pharmaceuticals and AI. During a fireside chat, Lilly’s CEO highlighted AI’s potential to transform drug development.

The lab will operate under a scientist-in-the-loop framework, connecting wet labs with dry labs for continuous learning. By integrating AI into drug discovery, researchers can simulate and test a large number of molecules at scale. The collaboration aims to model the complexities of biology and find new biological targets using AI.

At the J.P. Morgan Healthcare Conference, NVIDIA recognized leaders in AI and drug discovery with signed DGX Spark systems. The honorees included CEOs of companies developing AI models for protein structure prediction and drug design. NVIDIA also announced an expansion of the BioNeMo platform for AI-driven biology and drug discovery.

In addition to the partnership with Lilly, NVIDIA highlighted collaborations with Thermo Fisher for autonomous lab infrastructure and Multiply Labs for automated cell therapy manufacturing. The company’s full-stack AI platform is accelerating advancements in digital biology and drug discovery. J.P. Morgan Healthcare is a prominent event for healthcare professionals worldwide.

Read more at NVIDIA: CEOs of NVIDIA and Lilly Share ‘Blueprint for What Is Possible’ in AI and Drug Discovery